• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人细胞色素P450 3A(CYP3A)和P-糖蛋白的底物与抑制剂之间的相互关系

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

作者信息

Kim R B, Wandel C, Leake B, Cvetkovic M, Fromm M F, Dempsey P J, Roden M M, Belas F, Chaudhary A K, Roden D M, Wood A J, Wilkinson G R

机构信息

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6602, USA.

出版信息

Pharm Res. 1999 Mar;16(3):408-14. doi: 10.1023/a:1018877803319.

DOI:10.1023/a:1018877803319
PMID:10213372
Abstract

PURPOSE

CYP3A and P-gp both function to reduce the intracellular concentration of drug substrates, one by metabolism and the other by transmembrane efflux. Moreover, it has been serendipitously noted that the two proteins have many common substrates and inhibitors. In order to test this notion more fully, systematic studies were undertaken to determine the P-gp-mediated transport and inhibitory characteristics of prototypical CYP substrates.

METHODS

L-MDR1, LLC-PK1, and Caco-2 cells were used to evaluate established CYP substrates as potential P-gp substrates and inhibitors in vitro, and mdr1a deficient mice were used to assess the in vivo relevance of P-gp-mediated transport.

RESULTS

Some (terfenadine, erythromycin and lovastatin) but not all (nifedipine and midazolam) CYP3A substrates were found to be P-gp substrates. Except for debrisoquine, none of the prototypical substrates of other common human CYP isoforms were transported by P-gp. Studies in mdr1a disrupted mice confirmed that erythromycin was a P-gp substrate but the CYP3A-inhibitor ketoconazole was not. In addition, CYP3A substrates and inhibitors varied widely in their ability to inhibit the P-gp-mediated transport of digoxin.

CONCLUSIONS

These results indicate that the overlap in substrate specificities of CYP3A and P-gp appears to be fortuitous rather than indicative of a more fundamental relationship.

摘要

目的

细胞色素P450 3A亚家族(CYP3A)和P-糖蛋白(P-gp)均发挥作用以降低药物底物的细胞内浓度,一个通过代谢,另一个通过跨膜外排。此外,偶然发现这两种蛋白有许多共同的底物和抑制剂。为了更全面地验证这一观点,开展了系统研究以确定典型CYP底物的P-gp介导的转运和抑制特性。

方法

使用L-MDR1、LLC-PK1和Caco-2细胞在体外评估已确定的CYP底物作为潜在的P-gp底物和抑制剂,并使用mdr1a基因敲除小鼠评估P-gp介导的转运的体内相关性。

结果

发现一些(特非那定、红霉素和洛伐他汀)但并非所有(硝苯地平和咪达唑仑)CYP3A底物是P-gp底物。除了异喹胍,其他常见人类CYP同工酶的典型底物均未被P-gp转运。对mdr1a基因敲除小鼠的研究证实红霉素是P-gp底物,但CYP3A抑制剂酮康唑不是。此外,CYP3A底物和抑制剂在抑制P-gp介导的地高辛转运的能力上差异很大。

结论

这些结果表明CYP3A和P-gp底物特异性的重叠似乎是偶然的,而非表明存在更根本的关系。

相似文献

1
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.人细胞色素P450 3A(CYP3A)和P-糖蛋白的底物与抑制剂之间的相互关系
Pharm Res. 1999 Mar;16(3):408-14. doi: 10.1023/a:1018877803319.
2
Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.特非那定及其代谢产物在肠上皮Caco-2(TC7)细胞单层中CYP3A介导的代谢与极化外排之间的相互作用。
Pharm Res. 1999 May;16(5):625-32. doi: 10.1023/a:1018851919674.
3
Grapefruit juice activates P-glycoprotein-mediated drug transport.葡萄柚汁可激活P-糖蛋白介导的药物转运。
Pharm Res. 1999 Apr;16(4):478-85. doi: 10.1023/a:1011902625609.
4
Mdr1 limits CYP3A metabolism in vivo.多药耐药蛋白1(Mdr1)在体内限制细胞色素P450 3A(CYP3A)的代谢。
Mol Pharmacol. 2000 Oct;58(4):863-9. doi: 10.1124/mol.58.4.863.
5
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.P-糖蛋白与细胞色素P-450 3A抑制作用:抑制效力的解离
Cancer Res. 1999 Aug 15;59(16):3944-8.
6
Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.米贝拉地尔是一种P-糖蛋白底物,在体外是P-糖蛋白和CYP3A的强效抑制剂。
Drug Metab Dispos. 2000 Aug;28(8):895-8.
7
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein.人肝CYP450酶对依立曲坦的代谢及人P-糖蛋白对其的转运
Drug Metab Dispos. 2003 Jul;31(7):861-9. doi: 10.1124/dmd.31.7.861.
8
Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.P-糖蛋白相互作用以及红霉素、咪达唑仑和酮康唑在Caco-2细胞中的转运
Eur J Pharmacol. 1998 Oct 9;358(3):289-94. doi: 10.1016/s0014-2999(98)00607-4.
9
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.细胞色素P450 3A抑制剂与P-糖蛋白的相互作用。
J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. doi: 10.1124/jpet.102.037549.
10
The xenobiotic inhibitor profile of cytochrome P4502C8.细胞色素P4502C8的外源性物质抑制特征
Br J Clin Pharmacol. 2000 Dec;50(6):573-80. doi: 10.1046/j.1365-2125.2000.00316.x.

引用本文的文献

1
Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895.BTK抑制剂TL-895的药物相互作用风险
Cancer Res Commun. 2025 Sep 1;5(9):1621-1630. doi: 10.1158/2767-9764.CRC-25-0265.
2
Deciphering the Relative Contribution of CYP3A4 Versus P-Glycoprotein for the Shared Substrate Cyclosporine-Commentary on Lown et al.解读细胞色素P450 3A4(CYP3A4)与P-糖蛋白对共同底物环孢素的相对贡献——对洛恩等人研究的评论
Clin Pharmacol Ther. 2025 Jun;117(6):1546-1561. doi: 10.1002/cpt.3619.
3
Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool.

本文引用的文献

1
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].P-糖蛋白介导的药物转运的抑制作用:一种解释地高辛与奎尼丁相互作用的统一机制[见评论]
Circulation. 1999 Feb 2;99(4):552-7. doi: 10.1161/01.cir.99.4.552.
2
In vitro and in vivo drug interactions involving human CYP3A.涉及人细胞色素P450 3A的体外和体内药物相互作用。
Annu Rev Pharmacol Toxicol. 1998;38:389-430. doi: 10.1146/annurev.pharmtox.38.1.389.
3
Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.
临床试验数据驱动的药物相互作用风险评估:一种快速准确的决策工具。
Clin Pharmacokinet. 2024 Aug;63(8):1147-1165. doi: 10.1007/s40262-024-01404-0. Epub 2024 Aug 5.
4
Performance and Sensitivity of [Tc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver.与正电子发射断层显像放射性示踪剂相比,[锝]Tc-司他米比测量肾脏和肝脏中P-糖蛋白功能的性能及敏感性
Mol Pharm. 2024 Feb 5;21(2):932-943. doi: 10.1021/acs.molpharmaceut.3c01036. Epub 2024 Jan 15.
5
Preclinical evaluation of an F-labeled N-acryloyllysine piperazide for covalent targeting of transglutaminase 2.一种用于转谷氨酰胺酶2共价靶向的F标记N-丙烯酰赖氨酸哌嗪的临床前评估
EJNMMI Radiopharm Chem. 2024 Jan 2;9(1):1. doi: 10.1186/s41181-023-00231-1.
6
What Is Known about Midazolam? A Bibliometric Approach of the Literature.关于咪达唑仑我们了解什么?文献的文献计量学研究方法
Healthcare (Basel). 2022 Dec 28;11(1):96. doi: 10.3390/healthcare11010096.
7
Transgenic Expression of Cytochrome P450 Decreases Susceptibility to Particular but Not All Macrocyclic Lactones in the Model Organism .转基因表达细胞色素 P450 可降低模型生物对特定大环内酯类药物的敏感性,但不是所有大环内酯类药物。
Int J Mol Sci. 2022 Aug 15;23(16):9155. doi: 10.3390/ijms23169155.
8
Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.药物肝和肾 P-gp/BCRP 抑制的临床相关性:国际转运体联盟观点。
Clin Pharmacol Ther. 2022 Sep;112(3):573-592. doi: 10.1002/cpt.2670. Epub 2022 Jun 22.
9
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.在体外研究中考察了 CYP450 酶和药物转运体在共价 Bruton 酪氨酸激酶抑制剂 zanubrutinib 的药物相互作用中的作用。
Pharmacol Res Perspect. 2021 Dec;9(6):e00870. doi: 10.1002/prp2.870.
10
Influence of Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation.基因多态性对心房颤动患者利伐沙班血药浓度及出血事件的影响
Front Pharmacol. 2021 Apr 14;12:639854. doi: 10.3389/fphar.2021.639854. eCollection 2021.
Arch Biochem Biophys. 1998 Feb 15;350(2):340-7. doi: 10.1006/abbi.1997.0537.
4
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.药物转运体P-糖蛋白限制了HIV-1蛋白酶抑制剂的口服吸收和进入脑部。
J Clin Invest. 1998 Jan 15;101(2):289-94. doi: 10.1172/JCI1269.
5
The functional role of P-glycoprotein in the blood-brain barrier.P-糖蛋白在血脑屏障中的功能作用。
J Pharm Sci. 1997 Aug;86(8):881-4. doi: 10.1021/js9701364.
6
Apical enrichment of human EGF precursor in Madin-Darby canine kidney cells involves preferential basolateral ectodomain cleavage sensitive to a metalloprotease inhibitor.人表皮生长因子前体在马-达二氏犬肾细胞中的顶端富集涉及对金属蛋白酶抑制剂敏感的优先基底外侧胞外域裂解。
J Cell Biol. 1997 Aug 25;138(4):747-58. doi: 10.1083/jcb.138.4.747.
7
P-glycoprotein substrates and antagonists cluster into two distinct groups.
Mol Pharmacol. 1997 Jun;51(6):1024-33. doi: 10.1124/mol.51.6.1024.
8
Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.白人受试者与中国受试者在体内奥美拉唑对细胞色素P450 2C19、2D6和3A抑制作用上的差异。
Clin Pharmacol Ther. 1996 Oct;60(4):396-404. doi: 10.1016/S0009-9236(96)90196-4.
9
Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers.通过药理学化学增敏剂对P-糖蛋白介导的多药耐药性进行实验性逆转。
Eur J Cancer. 1996 Jun;32A(6):991-1001. doi: 10.1016/0959-8049(96)00047-0.
10
Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells.类固醇在多药耐药细胞中的治疗、蓄积及对P-糖蛋白的拮抗作用。
Biochemistry. 1996 Apr 16;35(15):4820-7. doi: 10.1021/bi952380k.